2342 related articles for article (PubMed ID: 17331172)
41. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease.
Fotiadu A; Gagalis A; Akriviadis E; Kotoula V; Sinakos E; Karkavelas G; Hytiroglou P
Pathol Int; 2010 Feb; 60(2):87-92. PubMed ID: 20398192
[TBL] [Abstract][Full Text] [Related]
43. [Nonalcoholic fatty liver hepatitis and fatty cirrhosis mimicking alcoholic liver diseases].
Spech HJ; Liehr H; Mitschke H
Z Gastroenterol; 1983 Nov; 21(11):651-9. PubMed ID: 6659631
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
[TBL] [Abstract][Full Text] [Related]
45. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
[TBL] [Abstract][Full Text] [Related]
46. Predictive factors for pure steatosis in alcoholic patients.
Naveau S; Thaury J; Barri-Ova N; Balian A; Dauvois B; Njiké-Nakseu M; Prévot S; Agostini H; Perlemuter G
Alcohol Clin Exp Res; 2009 Jun; 33(6):1104-10. PubMed ID: 19382900
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
[TBL] [Abstract][Full Text] [Related]
48. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis.
Torer N; Ozenirler S; Yucel A; Bukan N; Erdem O
Scand J Gastroenterol; 2007 Sep; 42(9):1095-101. PubMed ID: 17710676
[TBL] [Abstract][Full Text] [Related]
49. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.
Trak-Smayra V; Dargere D; Noun R; Albuquerque M; Yaghi C; Gannagé-Yared MH; Bedossa P; Paradis V
Gut; 2009 Jun; 58(6):825-32. PubMed ID: 18403495
[TBL] [Abstract][Full Text] [Related]
50. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report.
Tsuji Y; Kumashiro R; Ishii K; Arinaga T; Sakamoto Y; Tanabe R; Ogata K; Koga Y; Ide T; Ono N; Tanaka E; Abe H; Sata M
Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):26S-31S. PubMed ID: 12960503
[TBL] [Abstract][Full Text] [Related]
51. Body mass index and waist circumference in non-alcoholic fatty liver disease.
Rocha R; Cotrim HP; Carvalho FM; Siqueira AC; Braga H; Freitas LA
J Hum Nutr Diet; 2005 Oct; 18(5):365-70. PubMed ID: 16150132
[TBL] [Abstract][Full Text] [Related]
52. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
[TBL] [Abstract][Full Text] [Related]
53. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
54. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.
Shalhub S; Parsee A; Gallagher SF; Haines KL; Willkomm C; Brantley SG; Pinkas H; Saff-Koche L; Murr MM
Obes Surg; 2004 Jan; 14(1):54-9. PubMed ID: 14980034
[TBL] [Abstract][Full Text] [Related]
55. Non-alcoholic steatohepatitis in type 2 diabetes mellitus.
Gupte P; Amarapurkar D; Agal S; Baijal R; Kulshrestha P; Pramanik S; Patel N; Madan A; Amarapurkar A; Hafeezunnisa
J Gastroenterol Hepatol; 2004 Aug; 19(8):854-8. PubMed ID: 15242486
[TBL] [Abstract][Full Text] [Related]
56. [Nonalcoholic steatohepatitis--a "new" hepatic disease].
Grønbaek H; Eivindson MV; Hamilton-Dutoit S; Vilstrup H
Ugeskr Laeger; 2003 Mar; 165(11):1115-8. PubMed ID: 12677985
[TBL] [Abstract][Full Text] [Related]
57. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial.
Malaguarnera M; Gargante MP; Russo C; Antic T; Vacante M; Malaguarnera M; Avitabile T; Li Volti G; Galvano F
Am J Gastroenterol; 2010 Jun; 105(6):1338-45. PubMed ID: 20068559
[TBL] [Abstract][Full Text] [Related]
58. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
60. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension.
Cottone S; Mulè G; Nardi E; Vadalà A; Lorito MC; Guarneri M; Arsena R; Palermo A; Cerasola G
J Hypertens; 2007 Feb; 25(2):423-8. PubMed ID: 17211250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
